{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:05:53Z","timestamp":1793991953902,"version":"4.8.0"},"reference-count":56,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,10,2]],"date-time":"2022-10-02T00:00:00Z","timestamp":1664668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Primary biliary cholangitis (PBC) is a rare autoimmune cholestatic liver disease that may progress to fibrosis and\/or cirrhosis. Treatment options are currently limited. The first-line therapy for this disease is the drug ursodeoxycholic acid (UDCA), which has been proven to normalize serum markers of liver dysfunction, halt histologic disease progression, and lead to a prolongation of transplant-free survival. However, 30\u201340% of patients unfortunately do not respond to this first-line therapy. Obeticholic acid (OCA) is the only registered agent for second-line treatment in UDCA-non responders. In this review, we focus on the pharmacological features of OCA, describing its mechanism of action of and its tolerability and efficacy in PBC patients. We also highlight current perspectives on future therapies for this condition.<\/jats:p>","DOI":"10.3390\/biomedicines10102464","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T00:07:43Z","timestamp":1665187663000},"page":"2464","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Obeticholic Acid for Primary Biliary Cholangitis"],"prefix":"10.3390","volume":"10","author":[{"given":"Annarosa","family":"Floreani","sequence":"first","affiliation":[{"name":"Department of Surgery, Oncology and Gastroenterology, University of Padova, 35131 Padova, Italy"},{"name":"Scientific Institute for Research, Hospitalization and Healthcare, 37024 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2247-8227","authenticated-orcid":false,"given":"Daniela","family":"Gabbia","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 35131 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6398-8237","authenticated-orcid":false,"given":"Sara","family":"De Martin","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 35131 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41575-019-0226-7","article-title":"Primary Biliary Cholangitis: Pathogenesis and Therapeutic Opportunities","volume":"17","author":"Gulamhusein","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1111\/jgh.15329","article-title":"Regional Variation and Temporal Trend of Primary Biliary Cholangitis Epidemiology: A Systematic Review and Meta-analysis","volume":"36","author":"Lv","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/hep.29717","article-title":"Milder Disease Stage in Patients with Primary Biliary Cholangitis over a 44-year Period: A Changing Natural History","volume":"67","author":"Goet","year":"2018","journal-title":"Hepatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/gut.2003.023937","article-title":"Asymptomatic Primary Biliary Cirrhosis: Clinical Features, Prognosis, and Symptom Progression in a Large Population Based Cohort","volume":"53","author":"Prince","year":"2004","journal-title":"Gut"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1055\/s-2007-979469","article-title":"Interpreting Serological Tests in Diagnosing Autoimmune Liver Diseases","volume":"27","author":"Invernizzi","year":"2007","journal-title":"Semin. Liver Dis."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver, Hirschfield, G.M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., and Schramm, C. (2017). EASL Clinical Practice Guidelines: The Diagnosis and Management of Patients with Primary Biliary Cholangitis. J. Hepatol., 67, 145\u2013172.","DOI":"10.1016\/j.jhep.2017.03.022"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","article-title":"Ursodeoxycholic Acid Therapy and Liver Transplant-Free Survival in Patients with Primary Biliary Cholangitis","volume":"71","author":"Harms","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/S0140-6736(10)61965-4","article-title":"Primary Biliary Cirrhosis","volume":"377","author":"Selmi","year":"2011","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1053\/j.gastro.2012.12.005","article-title":"Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid","volume":"144","author":"Carbone","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.cgh.2018.12.028","article-title":"Effects of age and sex on response to ursodeoxycholic acid and transplant-free survival in patients with primary biliary cholangitis","volume":"17","author":"Cheung","year":"2019","journal-title":"Clin. Gastreonetrol. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jhep.2015.02.023","article-title":"New Paradigms in the Treatment of Hepatic Cholestasis: From UDCA to FXR, PXR and Beyond","volume":"62","author":"Beuers","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1021\/jm049904b","article-title":"Bile Acid Derivatives as Ligands of the Farnesoid X Receptor. Synthesis, Evaluation, and Structure-Activity Relationship of a Series of Body and Side Chain Modified Analogues of Chenodeoxycholic Acid","volume":"47","author":"Pellicciari","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.livres.2017.05.001","article-title":"Bile Acid Metabolism and Signaling in Liver Disease and Therapy","volume":"1","author":"Chiang","year":"2017","journal-title":"Liver Res."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Sayaf, K., Zanotto, I., Russo, F.P., Gabbia, D., and De Martin, S. (2021). The Nuclear Receptor PXR in Chronic Liver Disease. Cells, 11.","DOI":"10.3390\/cells11010061"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.3748\/wjg.v23.i42.7519","article-title":"Pregnane X Receptor and Constitutive Androstane Receptor Modulate Differently CYP3A-Mediated Metabolism in Early- and Late-Stage Cholestasis","volume":"23","author":"Gabbia","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1097-2765(00)00051-4","article-title":"A Regulatory Cascade of the Nuclear Receptors FXR, SHP-1, and LRH-1 Represses Bile Acid Biosynthesis","volume":"6","author":"Goodwin","year":"2000","journal-title":"Mol. Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"166145","DOI":"10.1016\/j.bbadis.2021.166145","article-title":"Emerging Functions of the Nuclear Receptor LRH-1 in Liver Physiology and Pathology","volume":"1867","author":"Sun","year":"2021","journal-title":"Biochim. Biophys. Acta (BBA)\u2014Mol. Basis Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.livres.2021.02.002","article-title":"Farnesoid X Receptor and Fibroblast Growth Factor 15\/19 as Pharmacological Targets","volume":"5","author":"Maliha","year":"2021","journal-title":"Liver Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1136\/gutjnl-2020-323345","article-title":"Sodium +\/Taurocholate Cotransporting Polypeptide as Target Therapy for Liver Fibrosis","volume":"71","author":"Salhab","year":"2022","journal-title":"Gut"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jhep.2012.08.002","article-title":"Bile Acid Transporters and Regulatory Nuclear Receptors in the Liver and Beyond","volume":"58","author":"Halilbasic","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.bbadis.2017.09.019","article-title":"Nuclear Receptor FXR, Bile Acids and Liver Damage: Introducing the Progressive Familial Intrahepatic Cholestasis with FXR Mutations","volume":"1864","author":"Cariello","year":"2018","journal-title":"Biochim. Biophys. Acta (BBA)\u2014Mol. Basis Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1158\/0008-5472.CAN-06-1078","article-title":"Spontaneous Development of Liver Tumors in the Absence of the Bile Acid Receptor Farnesoid X Receptor","volume":"67","author":"Yang","year":"2007","journal-title":"Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1053\/j.gastro.2004.08.001","article-title":"The Nuclear Receptor SHP Mediates Inhibition of Hepatic Stellate Cells by FXR and Protects against Liver Fibrosis","volume":"127","author":"Fiorucci","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","article-title":"NorUrsodeoxycholic Acid Improves Cholestasis in Primary Sclerosing Cholangitis","volume":"67","author":"Fickert","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.2353\/ajpath.2009.090114","article-title":"Farnesoid X Receptor Critically Determines the Fibrotic Response in Mice but Is Expressed to a Low Extent in Human Hepatic Stellate Cells and Periductal Myofibroblasts","volume":"175","author":"Fickert","year":"2009","journal-title":"Am. J. Pathol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Verbeke, L., Mannaerts, I., Schierwagen, R., Govaere, O., Klein, S., Vander Elst, I., Windmolders, P., Farre, R., Wenes, M., and Mazzone, M. (2016). FXR Agonist Obeticholic Acid Reduces Hepatic Inflammation and Fibrosis in a Rat Model of Toxic Cirrhosis. Sci. Rep., 6.","DOI":"10.1038\/srep33453"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1152\/physrev.00013.2007","article-title":"Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver","volume":"88","author":"Friedman","year":"2008","journal-title":"Physiol. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Gabbia, D., Cannella, L., and De Martin, S. (2021). The Role of Oxidative Stress in NAFLD\u2013NASH\u2013HCC Transition\u2014Focus on NADPH Oxidases. Biomedicines, 9.","DOI":"10.3390\/biomedicines9060687"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1053\/j.gastro.2011.10.028","article-title":"Selective Activation of Nuclear Bile Acid Receptor FXR in the Intestine Protects Mice Against Cholestasis","volume":"142","author":"Modica","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/bmb\/ldaa006","article-title":"Obeticholic Acid\u2014A New Therapy in PBC and NASH","volume":"133","author":"Chapman","year":"2020","journal-title":"Br. Med. Bull."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","author":"Kowdley","year":"2018","journal-title":"Hepatology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2468-1253(19)30094-9","article-title":"Long-Term Efficacy and Safety of Obeticholic Acid for Patients with Primary Biliary Cholangitis: 3-Year Results of an International Open-Label Extension Study","volume":"4","author":"Trauner","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/liv.14429","article-title":"Reduction and Stabilization of Bilirubin with Obeticholic Acid Treatment in Patients with Primary Biliary Cholangitis","volume":"40","author":"Shiffman","year":"2020","journal-title":"Liver Int."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.cgh.2019.09.050","article-title":"Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis","volume":"18","author":"Bowlus","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_36","first-page":"A98","article-title":"Long-term effect of obeticholic acid on transient elastography and AST to platelet ratio index in patients with PBC","volume":"66","author":"Hirschfield","year":"2017","journal-title":"Gut"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jhep.2020.07.028","article-title":"Obeticholic Acid Improves Hepatic Bile Acid Excretion in Patients with Primary Biliary Cholangitis","volume":"74","author":"Frisch","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_40","unstructured":"Obeticholic Acid (2012). No author listed, LiverTox: Clinical and Research Information on Drug-Induced Liver Injury."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/hep4.1518","article-title":"Real-World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis","volume":"4","author":"Roberts","year":"2020","journal-title":"Hepatol. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/apt.16181","article-title":"Effectiveness and Safety of Obeticholic Acid in a Southern European Multicentre Cohort of Patients with Primary Biliary Cholangitis and Suboptimal Response to Ursodeoxycholic Acid","volume":"53","author":"Gomez","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"D\u2019Amato, D., De Vincentis, A., Malinverno, F., Vigan\u00f2, M., Alvaro, D., Pompili, M., Picciotto, A., Palitti, V.P., Russello, M., and Storato, S. (2021). Real-World Experience with Obeticholic Acid in Patients with Primary Biliary Cholangitis. JHEP Rep., 3.","DOI":"10.1016\/j.jhepr.2021.100248"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: Biochemical response to treatment and prediction of long-term outcome","volume":"55","author":"Corpechot","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"De Vincentis, A., D\u2019Amato, D., Cristoferi, L., Gerussi, A., Malinverno, F., Lleo, A., and Colapietro, F. (2022). Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid. Liver Int., in press.","DOI":"10.1111\/liv.15386"},{"key":"ref_46","first-page":"1267","article-title":"Real World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis: The Global Experience","volume":"S1","author":"Gulamhusein","year":"2020","journal-title":"Hepatology"},{"key":"ref_47","first-page":"1268","article-title":"Real-World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis","volume":"S1","author":"Gish","year":"2020","journal-title":"Hepatology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Abbass, N., Culver, E.L., Thornburn, D., Halliday, N., Crothers, H., Dyson, J.K., Phaw, A., Aspinall, R., Khakoo, S.I., and Kallis, Y. (2022). UK-wide multicenter evaluation of second-line therapies in primary biliary cholangitis. Clin. Gastroenterol. Hepatol., in press.","DOI":"10.1136\/gutjnl-2021-BSG.18"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Murillo Perez, C.F., Fisher, H., Hin, S., Kareithi, D., Adekunle, F., Mayne, T., Malecha, E., Ness, E., van der Meer, A.J., and Lammers, W.J. (2022). Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls. Gastroenterology, S0016-5085(22)01060-5.","DOI":"10.1016\/S0016-5085(22)63549-2"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/hep.26894","article-title":"Peroxisome Proliferator-Activated Receptor \u03b1 Activates Human Multidrug Resistance Transporter 3\/ATP-Binding Cassette Protein Subfamily B4 Transcription and Increases Rat Biliary Phosphatidylcholine Secretion","volume":"59","author":"Ghonem","year":"2014","journal-title":"Hepatology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1002\/hep.26018","article-title":"Anticholestatic Effects of Bezafibrate in Patients with Primary Biliary Cirrhosis Treated with Ursodeoxycholic Acid","volume":"57","author":"Honda","year":"2013","journal-title":"Hepatology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0016-5085(19)32419-9","article-title":"Effects of Clofibrate in Primary Biliary Cirrhosis Hypercholesterolemia and Gallstones","volume":"69","author":"Summerfield","year":"1975","journal-title":"Gastroenterology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/apt.16336","article-title":"Combination of Fibrates with Obeticholic Acid Is Able to Normalise Biochemical Liver Tests in Patients with Difficult-to-Treat Primary Biliary Cholangitis","volume":"53","author":"Soret","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/hep.32117","article-title":"Primary Biliary Cholangitis: 2021 Practice Guidance Update from the American Association for the Study of Liver Diseases","volume":"75","author":"Lindor","year":"2022","journal-title":"Hepatology"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/10\/2464\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:45:27Z","timestamp":1760143527000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/10\/2464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,2]]},"references-count":56,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["biomedicines10102464"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines10102464","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,2]]}}}